ArticleOrphanet journal of rare diseases2023

Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond.

Antonio Toscano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.